| Target Professions: | DO, MD, Physician Associate/Assistant, Nurse Practitioner |
| Target Specialties: | Allergy and Immunology, Pulmonary/Respiratory, Family Medicine, Internal Medicine, Pediatrics |
| Credits Available: | 4.50 AMA PRA Category 1 Credit™ |
This curriculum enables asthma specialists to optimally select personalized treatment strategies using biologic agents for patients with severe uncontrolled asthma based on patient phenotypes, biomarker results, and comorbid conditions. Through practical guidance and case studies, participants will identify key signs and symptoms of severe asthma and risks of future exacerbations, review the indications, benefits and eligibility criteria of the 6 FDA-approved biologic agents, and determine when to switch or de-escalate treatments. This knowledge will help optimize long-term outcomes of patients with severe asthma.
Answer the following questions to assess your knowledge regarding the management of severe uncontrolled asthma.
Review type 2 inflammation in asthma, FDA-approved biologics, matching biologics with phenotypes and other patient criteria, and recommendations from GINA and other guidelines for help in selecting the most appropriate agent.
Address real-world challenges to the clinical application of biologic management despite the lack of clear frameworks, and use case-based scenarios to escalate, switch or de-escalate biologic therapies to optimize personalized management of severe asthma.
Answer the following questions to assess what you have learned about the management of severe uncontrolled asthma using biologic therapies.
This Live Group Discussion will focus on a case of a 40-year-old female with progressively worsening asthma symptoms. We will also address any questions you may have regarding the baseline and final assessments and the self-study modules.
In this activity you will meet Marta, a young woman diagnosed 6 years ago with mild allergic asthma. Her current symptoms and frequency of antibiotic prescriptions led to her referral to you.
In this activity you will meet Stephen who recently had a serious asthma exacerbation despite taking add-on mepolizumab. Please determine a treatment strategy.
Please share an action plan that you will implement to improve your ability to identify patients with severe uncontrolled asthma who would benefit from specialty referral for biologic therapies.
This Live Group Discussion will review a case of a 48-year-old man who is might need a different biologic medication for his uncontrolled asthma. We will also review your submissions on the Patient Case Challenges and Action Plans.
